Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...

Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...

The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...